On Feb 10 (see previous comments, they can be retrieved by putting PFE in the search engine!), Pfizer looked like a buy under $13 but given the overall stock market it might overshoot by one or two dollars (it did by 1 1/2 to about $11.62) so perhaps you bought at $12.50. from there we are up two dollars so one should still be in it. I would un till something else derails the thought , wait for at least 30% (16.25) or better yet, the 200 day moving average ( yellow) at about $18. The trigger for this move was the phase whatever trial for a pancreatic drug that was stopped in order for the placebo taking check group to join the party ( pancreatic cancer is for all intents and purposes the end, period.). My late father was once the CEO of Philips- Duphar, one of the largest Dutch pharma companies, and by osmosis I have learned from him that this is not a very transparent business as you do not necessarily get what you see. There was, and perhaps still is, a small Canadian company that worked on a similar product and , if I remember correctly , you could extend a patient’s life by perhaps at the most a few months at a cost of $30.000 or so. Not the kind of stuff blockbusters are made of. But in the mean time enjoy the ride, this sector has been beaten down for about 10 years now.